PharmaEssentia (6446 TW) stock market data APIs
NT$493.9804
-19.35(-3.9%)
as of January 2, 2026
Try our APIs with
free plan!
PharmaEssentia Financial Data Overview
Price chart is built with
Anychart
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
Prev. Close
493.9804
Open
474.6315
High
496.1469
Low
473.4144
52 wk Range
395.5448-715.5767
Market Cap
165 204 M
P/E Ratio
38.165
Shares Outstanding
334 M
Revenue
13 815 M
EPS
3.99
Dividends (Yield)
0.0021
Beta
-0.052
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with PharmaEssentia (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get PharmaEssentia data using free add-ons & libraries
Get PharmaEssentia Fundamental Data
PharmaEssentia Fundamental data includes:
- Net Revenue: 13 815 M
- EBITDA: 4 031 M
- Earnings Per Share: 12
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-04
- EPS/Forecast: 4.31
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
PharmaEssentia News
New
December 2025's Asian Stocks That May Be Trading Below Estimated Value
As we approach the end of 2025, Asian markets have shown resilience with notable gains in key indices, despite global economic challenges and mixed signals from major economies. In this context, ident...
Asian Market Value Picks: 3 Stocks Priced Below Estimated Intrinsic Value
As Asian markets continue to navigate a landscape of economic challenges and opportunities, investors are increasingly focused on identifying stocks that offer strong value propositions amid current c...
3 Asian Stocks Possibly Undervalued By Up To 48.3%
As global markets continue to navigate a complex landscape, Asian stocks have shown resilience, with indices like Japan's Nikkei 225 and China's CSI 300 posting gains amid optimism around artificial i...
3 Asian Stocks That May Be Undervalued In December 2025
As global markets close out the year, Asian indices have shown resilience amid a mixed economic landscape, with China's stock markets experiencing gains despite broader concerns about growth and inves...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
